Epizyme builds epigenetics lineup with $90M Celgene score

Epizyme has scored its richest pact yet, raking in $90 million in an upfront fee and equity payment from Celgene ($CELG) in return for an option to partner on the technology while gaining ex-U.S. righ…
Read the full story: News